arrow
Y

Yasuhisa Ohde

Shizuoka Cancer Center
H指数:33
被引数:3,713

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ASO Visual Abstract: Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II–III Lung Adenocarcinoma—A Multicenter CReGYT-03 ALK Study

ASO 可视化摘要:ALK 阳性 II–III 期肺腺癌辅助化疗的有限影响——一项多中心 CReGYT-03 ALK 研究

2026-10-230
PRE
Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II–III Lung Adenocarcinoma: A Multicenter CReGYT-03 ALK Study

ALK阳性II-IIIA期肺腺癌中辅助化疗的有限影响:一项多中心CReGYT-03 ALK研究

2026-10-050
PRE
ASO Visual Abstract: Perioperative Outcomes and Pathological Response After Neoadjuvant Nivolumab Plus Platinum Chemotherapy in Clinically Node-Negative Non-Small Cell Lung Cancer

ASO 可视化摘要:在临床 N0 期非小细胞肺癌中,新辅助尼鲁单抗联合铂类化疗的围手术期结局及病理学反应

2026-09-300
PRE
Evaluation of postoperative pain by PainVision® PS-2100, a quantitative analyzer for perception and pain in pulmonary resection: a prospective pilot study

使用PainVision® PS-2100(一种用于肺切除术后痛觉和疼痛感知的定量分析器)评估术后疼痛:一项前瞻性试点研究

2026-04-010
PRE
Comparison of treatment outcomes between stereotactic body radiotherapy/proton beam therapy and sublobar resection for vulnerable elderly patients with stage IA non-small cell lung cancer

比较立体定向体部放射治疗/质子束治疗与亚肺叶切除术在易损老年患者中针对ⅠA期非小细胞肺癌的治疗效果比较

2025-11-010
PRE
Safety Profile of Neoadjuvant Chemoimmunotherapy with Nivolumab for Patients with Resectable NSCLC in the Real-world (CReGYT-04 Neo-Venus)

纳武利尤单抗新辅助化免疫疗法在可切除非小细胞肺癌患者中的真实世界安全性分析 (CReGYT-04 Neo-Venus)

2025-10-300
PRE
Impact of the IASLC Grading and Other Pathological Features on Relapse and Survival in Completely Resected Lung Adenocarcinoma by EGFR Mutation Status: A Supplementary Analysis of the CReGYT-01 EGFR Study

IASLC分级及其他病理特征对完全切除的肺腺癌患者复发和生存的影响:按EGFR突变状态分类的CReGYT-01 EGFR研究的补充分析

2025-08-130
PRE
Adjuvant therapy in pStage IA1–IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study)

pStage IA1–IIA期肺腺癌(pN0)的辅助治疗:一项聚焦于EGFR突变和复发模式的多中心研究(CReGYT-01 EGFR研究)

2025-07-170
PRE
Longitudinal assessment of functional independence of older adults after lung cancer surgery: Final results of the JCOG1710A prospective cohort study

肺癌术后老年患者功能独立性的纵向评估:JCOG1710A前瞻性队列研究的最终结果

2025-05-300
OA
Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma

TP53共突变对切除的早期EGFR突变型肺腺癌的临床病理特征、预后、复发模式及复发后EGFR-TKI治疗疗效的影响

2025-04-250
PRE
Localization of epidermal growth factor receptor-mutations using PNA:DNA probes in clinical specimens from patients with non-small cell lung cancer

在非小细胞肺癌患者的临床标本中使用PNA:DNA探针定位表皮生长因子受体突变

2025-04-020
OAAI
Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study)
2024-11-211
PRE
Evaluation of whole genome sequencing utility in identifying driver alterations in cancer genome

评估全基因组测序在识别癌症基因组驱动改变中的效用

2024-10-120
OAAI
Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study
2024-04-011
PRE
NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study
2023-10-283
OA